Pursuant to Regulation 30 of Schedule III Part A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Concord Biotech has informed that investor’s presentation on Financial Results for the Third quarter and Nine months ended December 31, 2023 is enclosed.
The above information is a part of company’s filings submitted to BSE.